AMSACRINE IN REFRACTORY ACUTE-LEUKEMIA
- 1 January 1985
- journal article
- research article
- Vol. 69 (7-8) , 787-789
Abstract
Thirty-two patients with heavily pretreated, relapsed acute leukemia were treated with amsacrine (120 mg/m2 per day .times. 5). The 32 patients received a total of 41 courses of therapy, and 31 patients were evaluable for response. There were no complete remissions and only 1 partial remission (3 mo.) in an adult patient with acute lymphoblastic leukemia. Toxic effects included myelosuppression (100% of the patients), hyperbilirubinemia (41%), nausea and vomiting (41%), stomatitis (9%) and cardiac dysrhythmia (3%). Amsacrine as a single agent apparently is not a useful treatment for relapsed, heavily pretreated adult and pediatric acute leukemia.This publication has 11 references indexed in Scilit:
- Prediction of complete remission in patients with refractory acute leukemia treated with AMSA.Journal of Clinical Oncology, 1984
- INFLUENCE OF INTENSIVE ASPARAGINASE IN THE TREATMENT OF CHILDHOOD NON-T-CELL ACUTE LYMPHOBLASTIC-LEUKEMIA1983
- AMSACRINE IN REFRACTORY ADULT ACUTE-LEUKEMIA - A PILOT-STUDY OF THE SOUTHEASTERN-CANCER-STUDY-GROUP1983
- AMSA - A PROMISING NEW AGENT IN REFRACTORY ACUTE-LEUKEMIA1982
- EVALUATION OF AMSA IN PREVIOUSLY TREATED PATIENTS WITH ACUTE-LEUKEMIA - RESULTS OF THERAPY IN 109 ADULTS1982
- PHASE-II STUDY OF 4'-(9-ACRIDINYLAMINO)METHANESULFON-META-ANISIDIDE (NSC 249992) IN CHILDREN WITH ACUTE-LEUKEMIA AND LYMPHOMA1982
- CARDIAC ABNORMALITIES AFTER AMSA ADMINISTRATION1982
- Treatment of Acute Myelogenous Leukemia in Children and AdultsNew England Journal of Medicine, 1980
- 4′-(9-Acridinylamino) Methanesulfon-m-Anisidide (AMSA): A New Drug Effective in the Treatment of Adult Acute LeukemiaAnnals of Internal Medicine, 1980
- PHASE-I AND PHASE-II TRIAL OF 4'-(9-ACRIDINYLAMINO)METHANESULFON-META-ANISIDIDE IN PATIENTS WITH ACUTE-LEUKEMIA1980